Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity
Current Osteoporosis Reports · 2025-12 · 23 (1)
DOI: 10.1007/s11914-025-00902-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Osteoporosis Reports, online erschienen am 13.02.2025. Verfasst von Léa Karam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, MABlab ULR 4490, CHU Lille, University Lille, 2, Avenue Oscar Lambret, 59037, Lille Cedex, France. Hauptthemen laut MEDLINE: Bariatric Surgery, Osteoporosis, Obesity, Bone Density Conservation Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre Hospitalier Universitaire de Lille.
Abstract (Originalsprache)
Purpose This review focuses on recent findi+ngs regarding the management of adverse skeletal effects following weight loss in people living with obesity (PwO). We summarize the guidelines provided by various societies for the prevention and treatment of osteoporosis resulting from bariatric surgery. Next, we discuss the use of traditional antiosteoporosis medications in this population. Recent Findings Guidelines for preventing and treating osteoporosis resulting from bariatric surgery have been recently provided by various societies setting specific treatment criteria for postmenopausal women and men aged ≥ 50 years, based on the occurrence of fragility fractures and/or T-score thresholds. Several studies have highlighted the positive effects of lifestyle changes in preventing high-turnover bone loss; however, data on fracture outcomes are currently unavailable. It is generally accepted that following bariatric procedures, sufficient intake of calcium, vitamin D, and protein, along with regular exercise incorporating progressive, supervised resistance training, is crucial to counteract negative impacts on bone. Regarding the need for medications to combat osteoporosis, most societies recommend zoledronic acid as the preferred choice. This preference is due to the problems associated with oral bisphosphonates, including poor tolerance and absorption issues. Denosumab is typically considered the second choice when bisphosphonates are not suitable or well tolerated. Two randomized controlled studies have recently demonstrated the effectiveness and safety of zoledronic acid and denosumab in addressing high-turnover bone loss. Summary Although guidelines exist for managing skeletal health before and after bariatric surgery, more research is required to validate these recommendations and the use of anti-osteoporosis medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, MABlab ULR 4490, CHU Lille, University Lille, 2, Avenue Oscar Lambret, 59037, Lille Cedex, France.
- Saint-Joseph University, Beirut, Lebanon.
- Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon.
- Department of Rheumatology, MABlab ULR 4490, CHU Lille, University Lille, 2, Avenue Oscar Lambret, 59037, Lille Cedex, France. julien.paccou@chu-lille.fr.
Förderung
- Centre Hospitalier Universitaire de Lille
Zitieren
APA
Karam, L., & Paccou, J. (2025). Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity. Current Osteoporosis Reports, 23(1). https://doi.org/10.1007/s11914-025-00902-9
Vancouver
Karam L, Paccou J. Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity. Current Osteoporosis Reports. 2025;23(1). doi:10.1007/s11914-025-00902-9
BibTeX
@article{Karam2025,
author = {Karam, Léa and Paccou, Julien},
title = {Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity},
journal = {Current Osteoporosis Reports},
year = {2025},
volume = {23},
number = {1},
doi = {10.1007/s11914-025-00902-9}
}
EUVIMED